Skip to main content

Table 3 Changes in lab parameters and KCCQ

From: Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial

  Vitamin D 95% CI Placebo 95% CI p-value Corrected model p-value
BNP 30 ± 950 −10, 70 400 ± 1900 210–600 0.002* 0.003*
PTH −20 ± 20 −28, −11 7 ± 53 16, 30 <0.002* 0.07
hsCRP −1 ± 5 −3, 1 1 ± 6 −2, 4 0.18 0.21
25-(OH)D 51 ± 32 39,62 1 ± 6 −2, 3 <0.001* Na
Physical Score 9 ± 14 3,15 −5 ± 20 −4, 14 0.02* 0.07
Symptom Frequency 10 ± 28 −2, 28 −6 ± 17 −2, 13 0.03* 0.06
Symptom Burden 12 ± 20 3, 20 −7 ± 15 −14, 0 0.002* 0.05*
Total Symptom 11 ± 22 1, 22 −6 ± 17 −13, 1 0.013* 0.03*
Stability Score 3 ± 35 −13, 18 1 ± 14 −5,7 0.88 0.84
QOL Score 11 ± 21 3, 21 −2 ± 20 −11, 7 0.05* 0.11
Social Score 10 ± 24 0, 24 −4 ± 27 −16, 8 0.14 0.27
Overall Summary Score 10 ± 15 4,17 −6 ± 15 −13, 1 <0.02* 0.01*
Clinical Summary Score 8 ± 14 2, 14 −8 ± 18 −16, 0 0.02* 0.01*
  1. Data are expressed as mean ± SD, 95% CI
  2. Abbreviations: Kansas City Cardiomyopathy Questionnaire (KCCQ), Standard Deviation (SD), Confidence Interval (CI), B-type Natriuretic Peptide (BNP), Parathyroid Hormone (PTH), high sensitivity c-reactive protein (hsCRP), 25 hydroxyvitamin D (25-(OH)D), Quality of Life Score (QOL)
  3. *Indicates significant difference between groups